Search

Displaying results 4501 - 4510 of 10000 in total
  1. Drug

    VP025

    go.drugbank.com/drugs/DB05133
    Experimental

    It is considered to be a systemic anti-inflammatory and neuroprotective agent. … It is being developed to target the chronic inflammation within the central nervous system that is associated with a number of neurological diseases, including Alzheimer’s disease, Parkinson’s disease,

  2. Drug

    Glafenine

    go.drugbank.com/drugs/DB08963
    ApprovedWithdrawn

    An anthranilic acid derivative with analgesic properties used for the relief of all types of pain. Glafenine is withdrawn from the American market.

    Categories: Analgesics, Non-Narcotic
  3. Drug

    Gataparsen

    go.drugbank.com/drugs/DB05141
    Investigational

    LY2181308 is investigated in clinical trials for treating solid tumors. LY2181308 is a solid. LY2181308 is directed against a molecular target called survivin. … LY2181308 is known to target baculoviral IAP repeat-containing protein 5.

  4. Drug

    UCB-1184197

    go.drugbank.com/drugs/DB05092
    Investigational

    (now UCB S.A.) and is a putative new drug for oral treatment of multiple sclerosis. … CDP323 is an antagonist of the _vascular cell adhesion molecule 1_ (VCAM-1) binding to alpha4-integrins (other adhesion molecules), a process thought to be implicated in the pathophysiology of Multiple

  5. Drug

    NAV 1800

    go.drugbank.com/drugs/DB05437
    Experimental

    RIGScan CR49, a 125I-labelled CR monoclonal antibody directed against the tumour-associated antigen TAG-72, is undergoing development with Neoprobe for the intraoperative detection of metastatic colorectal

  6. Drug

    Gantenerumab

    go.drugbank.com/drugs/DB12034
    Investigational

    Despite the clear association of Aβ aggregation with AD, treatments aimed at preventing Aβ aggregation or removing pre-existing Aβ plaques have shown little to no clinical benefit thus far and remain controversial … Alzheimer's disease (AD) is the most common cause of dementia in elderly patients, with classical histopathological hallmarks including extracellular amyloid-beta (Aβ) plaques and intraneuronal neurofibrillary

  7. Drug

    DG041

    go.drugbank.com/drugs/DB05027
    Experimental

    DG041, an anti-platelet compound, has shown to be a selective and potent antagonist of the EP3 receptor for prostaglandins E2. … DG041 is a novel, first-in-class, orally-administered small molecule developmented for the prevention of arterial thrombosis and its complications.

  8. Drug

    Acumapimod

    go.drugbank.com/drugs/DB15448
    Investigational

    Acumapimod is under investigation in clinical trial NCT02926326 (The Effect of Azithromycin on BCT197 Exposure in Healthy Male Volunteers).

  9. Drug

    Eftansomatropin alfa

    go.drugbank.com/drugs/DB18460
    Investigational

    [L48275] It is under investigation for the treatment of growth hormone deficiency. … Eftansomatropin alfa (GX-H9) comprises a recombinant human growth hormone fused to hyFc, a synthetic hybrid Fc fragment.

  10. Drug

    Cimlanod

    go.drugbank.com/drugs/DB14983
    Investigational

    Cimlanod is under investigation in clinical trial NCT02819271 (A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers)